Revance Therapeutics Inc RVNC
$3.65 $3.65
Last Updated: Feb 06, 12:00 AM·BE
Pricing for DE stocks is delayed by 24 hours
Open navigation menu
Invest
Invest on your own
We do it for you
Halal tools
Screeners
Your portfolio
Calculators
Shariah
Our certifications
Learn
Education
Get help
Pricing
Company
About Musaffa
Investors
Build with us
Is Revance Therapeutics Inc Stock Halal?
Shariah Compliance Analysis of RVNC Stock
Germany Health Care Small Cap No. As of September 2026, Revance Therapeutics Inc (RVNC) is classified as NOT HALAL by Musaffa under its AAOIFI-based Shariah screening methodology. Revance Therapeutics Inc does not pass Musaffa's business and financial screening criteria.
Revance Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The company is headquartered in Nashville, Tennessee and currently employs 597 full-time employees. The company went IPO on 2014-02-06. The firm's portfolio includes DAXXIFY (DaxibotulinumtoxinA-lanm) for injection and the RHA Collection of dermal fillers in the United States. The company has also partnered with Viatris to develop a biosimilar to onabotulinumtoxinA for injection and Fosun to commercialize DAXXIFY in China. Its product/product candidate includes DAXXIFY for glabellar lines indication; DAXXIFY for cervical dystonia indication; RHA Redensity for perioral rhytids indication; RHA 2/ RHA 3/ RHA 4 for facial wrinkles and folds (such as nasolabial folds) indication; DAXXIFY for forehead lines, lateral canthal lines, upper facial lines indication; DAXXIFY for upper limb spasticity indication, and onabotulinumtoxinA biosimilar. The firm has exclusive right to import, market, promote, sell and distribute Teoxane's line of Resilient Hyaluronic Acid dermal fillers.
RVNC Shariah Compliance
Screening Methodology: AAOIFI
As of September 2026, Revance Therapeutics Inc is classified as not halal.
NOT HALAL
Report Source: undefined Quarter Report
Revance Therapeutics Inc (RVNC) Chart
Financial Metrics & Statements of Revance Therapeutics Inc (RVNC)
FAQ's for Revance Therapeutics Inc (RVNC)
- As of September 2026, Revance Therapeutics Inc RVNC is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Revance Therapeutics Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Revance Therapeutics Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Revance Therapeutics Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Revance Therapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Revance Therapeutics Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Alternate Halal Stocks for Revance Therapeutics Inc (RVNC)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
